Biomedical subjects

A Milan

Publications and source records attributed to A Milan.

7 recordsLinked to original sources

PubMed2005

Energy cost of swimming of elite long-distance swimmers.

The aim of this study was: (1) to assess the energy cost of swimming (C(s), kJ km(-1)) in a group of male (n = 5) and female (n = 5) elite swimmers specialised in long-distance competitions; (2) to evaluate the possible effect of a 2-km trial on the absolute value of C(s). C(s) was assessed during three consecutive 400-m trials covered in a 50-m pool at increasing speeds (v1, v2, v3). After these experiments the subjects swam a 2-km trial at the 10-km race speed (v2km) after which the three 400-m trials were repeated at the same speed as before (v5 = v1, v6 = v2, v7 = v3). C(s) was calculated by dividing the net oxygen uptake at steady state VO2ss by the corresponding average speed (v, m s(-1)). VO2ss was estimated by using back extrapolation technique from breath-to-breath VO2 recorded during the first 30 s of recovery after each test. C(s) increased (from 0.69 kJ m(-1) to 1.27 kJ m(-1)) as a function of v (from 1.29 m s(-1) to 1.50 m s(-1)), its values being comparable to those measured in elite short distance swimmers at similar speeds. In both groups of subjects the speed maintained during the 2-km trial (v2km) was on the average only 1.2% faster than of v2 and v6 (P>0.05), whereas C(s) assessed at the end of the 2-km trial (v2km) turned out to be 21 +/- 26% larger than that assessed at v2 and v6 (P<0.05); the average stroke frequency (SF, cycles min(-1)) during the 2-km trial turned to be about 6% (P<0.05) faster than that assessed at v2 and v6. At v5, C(s) turned out to be 19 +/- 9% (P<0.05) and 22 +/- 27% (0.1 < P = 0.05) larger than at v1 in male and female subjects (respectively). SF was significantly faster (P<0.05, in male subjects) and the distance per stroke (Ds = v/SF) significantly shorter (P<0.05) in female subjects at v5 and v6 than at v1 and v2. These data suggest that the increase of C(s) found after the 2-km trial was likely related to a decrease in propelling efficiency, since the latter is related to the distance per stroke.

Adult↗

PubMed2004

Antitussive activity of iodo-resiniferatoxin in guinea pigs.

BACKGROUND: Iodo-resiniferatoxin (I-RTX) has recently been described as an ultra potent antagonist of the transient receptor potential vanilloid-1 (TRPV1). METHODS: The ability of I-RTX to inhibit cough induced by inhalation of two putative TRPV1 stimulants (capsaicin and citric acid) was tested in non-anaesthetised guinea pigs. RESULTS: Pretreatment with I-RTX either intraperitoneally (0.03-0.3 micromol/kg) or by aerosol (0.1-3 microM) reduced the number of coughs produced by inhalation of citric acid (0.25 M) and capsaicin (30 microM) in a dose dependent manner. Capsazepine (CPZ) also reduced citric acid and capsaicin induced cough, but the activity of I-RTX was 10-100 times more potent than CPZ in all the experimental conditions tested. CONCLUSIONS: I-RTX is a novel and potent antitussive drug which inhibits cough mediated by agents possibly acting via TRPV1 activation.

Animals↗

PubMed2001

Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension.

The resistant hypertension has been differentiated in true resistant hypertension and white-coat resistant hypertension by using ambulatory blood pressure monitoring. White-coat resistant hypertension was defined as high clinic blood pressure, despite triple treatment for at least 3 months, but day-time blood pressure values < 135/85 mmHg. The aim of this study was to evaluate the presence of different clinical characteristics between two types of resistant hypertension. The study group consisted of 49 patients with essential hypertension, resistant to an adequate and appropriate triple-drug therapy, that included a diuretic, with all 3 drugs prescribed in near maximal doses and that had persistently elevated clinic blood pressure (> 140/90 mm Hg), for at least 3 months. They represented the 2% of 2500 hypertensive outpatients that referred at our Hypertension Unit. Patients with white-coat resistant hypertension (n=19) were older (p<0.05) than those with true resistant hypertension (n=30). The sodium intake (p<0.05) and alcohol intake (p<0.05) were significantly higher in patients with true resistant hypertension than in those with white-coat resistant hypertension. The renin plasma activity and plasma aldosterone were higher (p<0.05) in patients with true resistant hypertension than in those with white-coat resistant hypertension with normal plasma electrolyte balance. There were no significant differences in mean values of office systolic and diastolic blood pressures between white coat resistant hypertensives and true resistant hypertensives (165+17 vs 172+28 and 98+12 vs 102+14 mmHg). Day-time and night-time ambulatory 24-h-systolic and diastolic blood pressures were significantly higher in the true resistant hypertensive patients when compared with white-coat resistant hypertensives (153+15 vs 124+10 mmHg and 97+9 vs 76+6 mmHg all p<0.001). Day-time and night-time ambulatory 24-h-heart rate were significantly higher in the true resistant hypertensive patients when compared with white-coat resistant hypertensives (79+11 vs 71+9 beats/min; p<0.01; 68+9 vs 60+6 beats/min, p<0.001). The ABP readings were analysed by a Fourier series with 4 harmonics. According to the runs test both two groups of patients showed a circadian rhythm for both systolic and diastolic blood pressure. The nocturnal fall in SBP, DBP and HR was not different in both groups of patients. In conclusion, our findings showed that true resistant hypertensive patients were characterized both by higher heart rate and higher plasma renin activity values as an expression of a possible increased sympathetic activity. Thus, the combination of ABPM with the assessment of the clinical characteristics allow to differentiate better the true drug-resistant hypertension from the white coat resistant hypertension.

Aged↗

PubMed1993

Activity of inspiratory neurones of the ambiguus complex during cough in the spontaneously breathing decerebrate cat.

In spontaneously breathing, decerebrate cats, extracellular recordings in the intermediate region of the ambiguus complex have been used to characterize the activity of inspiratory laryngeal motoneurones (ILMNs) during mechanical stimulation of tracheal irritant receptors. Laryngeal resistance was measured using an isolated larynx in situ. The effect of tracheal stimulation was analysed successfully in twenty-seven neurones. Eleven were ILMNs and sixteen inspiration-related neurones. Inspiration-related neurones increased their phasic discharge frequency during tracheal stimulation while ILMNs fired tonically, during both the inspiratory and the expiratory efforts of the cough. The tonic discharge of ILMNs coincided with a decrease of laryngeal resistance.

Afferent Pathways↗

PubMedDate not supplied

Obesity and autonomic function in adolescence.

Hypertension and obesity are risk factors for coronary heart diseases in adults. In turn, childhood overweight and high blood pressure increase the risk of subsequent obesity and hypertension in adulthood. Human obesity is characterized by profound alterations of hemodynamic and metabolic states. Whether these alterations involve sympathetic nervous system control on cardiac function is controversial. We report the results of our study, conducted in a sample of obese adolescents by using power spectral analysis of heart rate variability. An increase in sympathetic tone coupled with a reduction in vagal tone was found. This allowed us to hypothesize that autonomic nervous system changes depend on the time course of obesity development. It is still unclear if treatment of obesity in adolescence prevents subsequent autonomic imbalance and hypertension.

Adolescent↗

PubMedDate not supplied

Baroreflex sensitivity in secondary hypertension.

A deranged baroreceptor control of the cardiovascular functions has been reported in essential hypertension. Studies performed in experimental animals and in humans using different approaches have documented an impairment of both baroreflex heart rate modulation (resetting and loss of sensitivity) and baroreceptor control of peripheral vasomotor tone (only resetting). Baroreflex alterations have been reported also in secondary forms of hypertension, but data are controversial. This paper reviews recent works concerning baroreflex function in secondary hypertension. Either structural changes of arterial wall (decrease of vascular distensibility) or functional processes (involving angiotensin II, aldosterone, catecholamines, nitric oxide) have been proposed as potential mechanisms responsible for baroreflex readjustments in secondary hypertension. It remains unclear, and it is difficult to define exactly, if baroreflex changes associated with secondary form of hypertension are primarily due to factors specific for different hypertensive conditions, or merely follow blood pressure elevation.

Adrenal Gland Neoplasms↗

PubMedDate not supplied

Antihypertensive drugs and sympathetic nervous system.

Several studies have demonstrated that essential hypertension is accompanied by sympathetic activation, which contributes to blood pressure elevation. Sympathetic activation also has adverse consequences in hypertensive patients beyond initiating blood pressure elevation. There is evidence that neural vasoconstriction has metabolic effects in skeletal muscle, impairing glucose delivery to muscles. In the liver, retarding of post prandial clearance of lipids contributes to hyperlipidemia. Cardiac sympathetic activation is a probable cause of sudden death in hearth failure. A trophic effect of sympathetic activation on cardiovascular growth is also likely, contributing to the development of left ventricular hypertrophy. Consequently, one of the major aims of antihypertensive therapy should be to attenuate sympathetic tone. It is possible that, among the antihypertensive drugs available, those inhibiting the sympathetic nervous system might best reduce cardiovascular risk.

Adrenergic alpha-Antagonists↗